BEVERLY, Mass.--(BUSINESS WIRE)-- INVO Bioscience (OTC BB: IVOB) announced that CECOLFES (http://cecolfes.com/), Colombia Fertility Center, Bogota, Colombia, the first center in Latin America to introduce the INVOcell device and the INVO procedure for treatment of infertility, made known today the results of the first 28 cycles of the INVO procedure. Of the 28 patients treated, 27 patients had embryos transferred and 10 patients became pregnant with only one patient having a multiple pregnancy. This results in a 36% ongoing pregnancy rate per cycle. The average patient age was 34 years old with an average number of 6 oocytes (eggs) retrieved per patient. “We are very happy with these initial results and the patients love being involved in the process. The procedure is easy to perform and we are happy to be pioneering the INVO procedure,” said Dr. Elkin Lucena, who owns and runs the CECOLFES fertility center. He continued “We have many more patients being treated with INVO. These results validate the efficacy of the INVO procedure and we expect to perform INVO in replacement of conventional IVF,” said Lucena. CECOLFES has also opened several INVO clinics within the region.
